George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Alusid raises £1.34m to scale up manufacturing

18 Sep 2018 13:56

RNS Number : 1499B
Frontier IP Group plc
18 September 2018
 

RNS / RNS

AIM: FIPP

18 September 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Alusid raises £1.34 million to scale up manufacturing of innovative, sustainable building materials

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that portfolio company, Alusid Limited (the "Company" or "Alusid"), has raised £1.34 million through a private funding round to support the design, planning and location of a new factory to transform its production capacity.

 

The fundraising has been supported by new and existing investors, including Frontier IP. The Group has converted a £348,000 loan into new equity in Alusid.

 

The fundraising values the Company at £4.86 million, meaning Frontier IP's 35.6 per cent stake is worth £1.73 million, up from the previous valuation of £700,000 for the 39 per cent held pre-fundraising. The funding round remains open for further investment up to a total of £1.75 million until 31 December 2018.

 

University of Central Lancashire spin-out Alusid uses a patented process to manufacture sustainable, high-quality building materials by recycling industrial waste ceramics and glass, which would otherwise go to landfill. Products are sold under the brand name SilicaStone.

 

Currently, the company makes table tops, tiles and other surfaces through a batch process using three kilns at its plant in Preston, Lancashire.

 

The proceeds of the fundraising will be invested in developing a new factory based on a continuous flow process, where products are fired by being fed onto a conveyer belt system, called a roller hearth tunnel kiln, in a steady stream.

 

The move follows the successful testing of a pilot production line with world-leading Italian ceramic -equipment company, Sacmi Group, which will also help to design the new factory. The Alusid process means the factory will be much more energy efficient than those used for making conventional tiles.

 

The plant is expected to start production in 2020. Once it is in operation, Alusid's capacity will rise from 4,000m2 a year to 30,000m2 a month, based on a single line producing tiles. Currently, it is estimated the cost of building a factory is about £10 million. Options being explored to finance the build include an initial public offering.

 

Alusid is attracting strong interest, and currently has more than 100 projects in its pipeline. SilicaStone buyers include Amazon, Four Seasons Hotels, Nando's and Wells Fargo bank, which is using the material in its prestigious new London HQ. The Company won this year's Jonathan Hindle Prize for outstanding design in 2D materials, awarded by The Furniture Makers' Company.

 

The Company is also actively exploring opportunities for international expansion, either through licensing or establishing joint ventures. Initial interest has been expressed by organisations in the United States, China and Portugal.

 

Allenby Capital Limited acted as broker to Alusid in connection with the funding round.

 

Alusid co-founder and chief operating officer Dr Alasdair Bremner said: "The building industry is increasingly looking for innovative sustainable products such as SilicaStone. This successful fund-raising will enable Alusid to move to the next stage in development where we can really capitalise on the economies of scale coupled with lower energy and material costs." 

 

Frontier IP chief executive Neil Crabb said: "We're delighted with the success of the Alusid funding round and the belief shown by investors in the potential of the Company. With consumers increasingly focused on sustainability and the impact of waste on the environment, we are confident that Alusid has a very bright future."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications and Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of material equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFFFEAFASEIU
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.